Imagine a high-tech camera that takes millions of pictures of cells, but a human has to sort through them all by hand to find a disease. This project built a smart cloud-based brain that does the sorting automatically and accurately. It also includes special biological markers that act like glowing tags to show how cells are eating and breathing, which helps spot sicknesses earlier.
Clinical flow cytometry is hindered by a reliance on manual data analysis, which is slow, error-prone, and requires high coding skills. Additionally, there is a lack of biomarkers to track cell metabolism in diseases.
A cloud-based AI software for automated flow cytometry analysis and a set of proprietary RBD biomarkers for metabolism tracking.
If you are a diagnostic laboratory dealing with slow, manual data interpretation and human error — this project developed a clinical-grade AI platform that provides objective and reproducible results. It replaces cumbersome manual analysis to speed up patient diagnosis.
If you are a biotech firm dealing with the inability to track cell metabolism in disease models — this project developed proprietary RBD biomarkers that bind to nutrient transporters. This allows for the characterization of cell metabolism during the discovery phase.
If you are a health-IT provider dealing with the lack of regulatory-compliant analysis tools for flow cytometry — this project developed a cloud-based software fulfilling 21 CFR Part 11/820 and CE-IVD standards. This enables seamless integration into regulated clinical environments.
The platform is positioned to be delivered via a SaaS (Software as a Service) business model.
Yes, the project specifically worked on the platform architecture to ensure it can go to scale and be integrated into clinical environments.
The project utilizes proprietary biomarkers called RBDs that characterize cell metabolism by binding to nutrient transporters.
Yes, the software is developed to fulfill regulatory expectations of 21 CFR Part 11/820 and CE-IVD.
Based on available project data, it is a cloud-based software designed to make existing flow cytometry instruments smarter by providing automated analysis of the data they generate.
The project is led by a single French SME, Metafora Biosystems, which holds 100% of the industry ratio. This lean structure suggests a highly focused development cycle where the coordinator retains full control over the IP and commercialization strategy of the METAflow platform.
Contact Metafora Biosystems in France for SaaS licensing inquiries.
Contact us to explore integration of AI-driven flow cytometry analysis into your diagnostic workflow.
